- Home
- TPST vs AIFF Comparison
TPST vs AIFF Comparison
Compare TPST & AIFF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- AIFF
- Stock Information
- Founded
- TPST 2011
- AIFF 2006
- Country
- TPST United States
- AIFF Canada
- Employees
- TPST N/A
- AIFF N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- AIFF
- Sector
- TPST Health Care
- AIFF
- Exchange
- TPST Nasdaq
- AIFF NYSE
- Market Cap
- TPST 27.2M
- AIFF 26.6M
- IPO Year
- TPST N/A
- AIFF N/A
- Fundamental
- Price
- TPST $0.93
- AIFF $3.85
- Analyst Decision
- TPST Strong Buy
- AIFF
- Analyst Count
- TPST 4
- AIFF 0
- Target Price
- TPST $20.00
- AIFF N/A
- AVG Volume (30 Days)
- TPST 1.8M
- AIFF 7.1M
- Earning Date
- TPST 11-12-2024
- AIFF 02-21-2025
- Dividend Yield
- TPST N/A
- AIFF N/A
- EPS Growth
- TPST N/A
- AIFF N/A
- EPS
- TPST N/A
- AIFF N/A
- Revenue
- TPST N/A
- AIFF $74,000.00
- Revenue This Year
- TPST N/A
- AIFF N/A
- Revenue Next Year
- TPST N/A
- AIFF N/A
- P/E Ratio
- TPST N/A
- AIFF N/A
- Revenue Growth
- TPST N/A
- AIFF N/A
- 52 Week Low
- TPST $0.70
- AIFF $1.86
- 52 Week High
- TPST $6.00
- AIFF $15.90
- Technical
- Relative Strength Index (RSI)
- TPST 54.03
- AIFF 66.67
- Support Level
- TPST $0.86
- AIFF $2.80
- Resistance Level
- TPST $1.05
- AIFF $4.18
- Average True Range (ATR)
- TPST 0.08
- AIFF 0.57
- MACD
- TPST 0.01
- AIFF 0.18
- Stochastic Oscillator
- TPST 52.92
- AIFF 50.51
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About AIFF FIREFLY NEUROSCIENCE INC
Firefly Neuroscience Inc is an AI company developing innovative neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support better outcomes for people suffering from mental illnesses and cognitive disorders.